CYPHERPUNK TECHNOLOGIES INC. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $234.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-12-31 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-09-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2024-06-30 was $234.00K.
- CYPHERPUNK TECHNOLOGIES INC. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2024 was $234.00K.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $234.00K derived: sum of 3 quarters · filed 2026-03-16 | $234.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $234.00K derived: sum of 2 quarters · filed 2025-11-12 | $234.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $234.00K 10-Q · filed 2025-08-14 | $234.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |